BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 12675724)

  • 1. RBC transfusion requirements after allogeneic marrow transplantation: impact of the before-transplant Hb level on transfusion and early survival.
    Xenocostas A; Yee A; Wong CJ; Sutton DM; Lipton JH; Kiss TL; Messner HA
    Transfusion; 2003 Mar; 43(3):373-82. PubMed ID: 12675724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher Anti-A/B isoagglutinin titers of IgG class, but not of IgM, are associated with increased red blood cell transfusion requirements in bone marrow transplantation with major ABO-mismatch.
    De Santis GC; Garcia-Silva AC; Dotoli GM; de Castro PT; Simões BP; Covas DT
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28160319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfusion requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient ABO incompatibility.
    Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Treleaven J
    Bone Marrow Transplant; 1996 Jul; 18(1):151-6. PubMed ID: 8832008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABO blood group barrier in allogeneic bone marrow transplantation revisited.
    Seebach JD; Stussi G; Passweg JR; Loberiza FR; Gajewski JL; Keating A; Goerner M; Rowlings PA; Tiberghien P; Elfenbein GJ; Gale RP; van Rood JJ; Reddy V; Gluckman E; Bolwell BJ; Klumpp TR; Horowitz MM; Ringdén O; Barrett AJ;
    Biol Blood Marrow Transplant; 2005 Dec; 11(12):1006-13. PubMed ID: 16338623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematological support in patients undergoing allogenetic bone marrow transplantation.
    Osterwalder B; Gratwohl A; Reusser P; Tichelli A; Speck B
    Recent Results Cancer Res; 1988; 108():44-52. PubMed ID: 3051211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft-versus-host disease and survival after ABO-incompatible allogeneic bone marrow transplantation: a single-centre experience.
    Stussi G; Seebach L; Muntwyler J; Schanz U; Gmür J; Seebach JD
    Br J Haematol; 2001 Apr; 113(1):251-3. PubMed ID: 11328309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
    Hosoba S; Waller EK; Shenvi N; Graiser M; Easley KA; Al-Kadhimi Z; Andoh A; Antun AG; Barclay S; Josephson CD; Koff JL; Khoury HJ; Langston AA; Zimring JC; Roback JD; Giver CR
    Biol Blood Marrow Transplant; 2018 May; 24(5):973-982. PubMed ID: 29307717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
    Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
    Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled trial of recombinant human erythropoietin after bone marrow transplantation.
    Link H; Boogaerts MA; Fauser AA; Slavin S; Reiffers J; Gorin NC; Carella AM; Mandelli F; Burdach S; Ferrant A
    Blood; 1994 Nov; 84(10):3327-35. PubMed ID: 7949088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation.
    Bacigalupo A; Van Lint MT; Occhini D; Margiocco M; Ferrari G; Pittaluga PA; Frassoni F; Peralvo J; Lercari G; Carubia F
    Transplantation; 1988 Jun; 45(6):1091-4. PubMed ID: 3289150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning.
    Badros A; Tricot G; Toor A; Morris C; Guo C; Munshi N; Barlogie B; Cottler-Fox M
    Transfusion; 2002 Feb; 42(2):205-9. PubMed ID: 11896336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse.
    Ustün C; Arslan O; Beksaç M; Koç H; Gürman G; Ozçelik T; Yilmaz B; Ilhan O; Akan H; Ozcan M; Demirer T; Uysal A; Konuk N; Arat M; Dilek I; Celebi H; Coskun HS
    Biol Blood Marrow Transplant; 1999; 5(1):28-35. PubMed ID: 10232738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
    Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
    Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RBC and platelet transfusion support in the first 30 and 100 days after haploidentical hematopoietic stem cell transplantation.
    Yuan S; Yang D; Nakamura R; Zhuang L; Al Malki MM; Wang S
    Transfusion; 2019 Nov; 59(11):3371-3385. PubMed ID: 31599972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfusion management of sickle cell patients during bone marrow transplantation with matched sibling donor.
    McPherson ME; Anderson AR; Haight AE; Jessup P; Castillejo MI; Hillyer CD; Josephson CD
    Transfusion; 2009 Sep; 49(9):1977-86. PubMed ID: 19453984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Increased risk of severe acute graft-versus-host disease in low body mass index patients undergoing haploidentical allogeneic stem cell transplantation].
    Chen Y; Xu L; Liu D; Liu K; Chen H; Zhang X; Wang F; Wang J; Wang Y; Han W; Chen Y; Yan C; Zhao T; Huang X
    Zhonghua Nei Ke Za Zhi; 2014 Sep; 53(9):710-4. PubMed ID: 25511404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.